$591 | SAVE $104 | Single User
$1186 | SAVE $209 | Global License

Physician Views: What does the future hold for new EGFR targeting NSCLC therapies?
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 19 Jun 2014 | 132 | In Stock
Related Topics: AstraZeneca , Boehringer Ingelheim , Roche

Introduction

Scope



Propelled via momentum from new data presented at the ASCO annual meeting, AstraZeneca's AZD-9291 and Clovis Oncology's CO-1686 look poised to advance the treatment paradigm for EGFR-positive non-small-cell lung cancer (NCSLC) patients over the next 12 to 18 months.


Both products are initially being developed for patients who have seen their disease progress after treatment with currently available targeted therapies, by selection of those EGFR-positive patients with the T790m mutation – which causes approximately half of the cases of acquired resistance to therapy with Tarceva (erlotinib; Roche), Iressa (gefitinib; AstraZeneca) and Gilotrif (afatinib; Boehringer Ingelheim).


The key question being asked post-ASCO is which product – AZD-9291 or CO-1686 – is superior? It is probably too soon to provide a definitive answer, but initial assessment of both products has focused primarily on side-effect profiles, given that in patients with the T790m-positive mutation AZD-9291 and CO-1686 have demonstrated comparable response rates.


While side effects for both products based on currently available data are treatable, a notable point of discussion around ASCO was increased risk of developing hyperglycaemia with CO-1686, which has caused some patients receiving the drug to also be treated with diabetes therapies. In addition, CO-1686 shows QTc prolongation, while AZD-9291 appears to have a worse side-effect profile in terms of rash and gastrointestinal events (thought to be due to slightly more pronounced off-target activity in hitting wild-type T790m negative) and also demonstrates more interstitial lung disease (ILD).


See Friday Five – 5 questions raised this week in pharma (ASCO edition) and ViewPoints: AstraZeneca senses chance to leapfrog Clovis in NSCLC race.


A second point under discussion is the possibility of eventual use for these two drugs as a first-line targeted therapy (i.e. instead of Tarceva, Iressa or Gilotrif). While AstraZeneca has been more cautious in this approach and has only recently announced that it will initiate a Phase III study (although conversely two-thirds of the company's peak forecast sales of billion for AZD09291 are attached to first-line usage), Clovis is set to begin head-to-head studies for CO-1686 versus Tarceva in the current quarter. It is assumed that data from the TIGER1 study – a randomised Phase II/III registration study of CO-1686 versus Tarceva in newly diagnosed EGFR mutant patients (not screened for T790m-positive status – will be presented at next year's ASCO meeting.


Puchase Reasons


To gain better physician insight on the potential future role of these two therapies, FirstWord is polling oncologists based in the US and EU5 with the following questions...


  • Based on currently available data, whether one of AZD-9291 or CO-1686 has a stronger overall clinical profile?

  • What is the potential opportunity for use of AZD-9291 and CO-1686 ahead of current EGFR therapies such as Tarceva based on current data?

  • What progression-free survival (PFS) benefit CO-1686 would have to demonstrate in the TIGER1 study to drive moderate switching into first-line targeted therapy patients?

  • Where in the treatment paradigm these T790m-positive targeting therapies are likely to be used most based on available data and physician enthusiasm?

  • Which product among the currently available EGFR inhibitors they expect to lose most market share at the expense of CO-1686 and/or AZD-9291?

  • Table of Contents
    for Physician Views: What does the future hold for new EGFR targeting NSCLC therapies? [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    132 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    SAVE 15% today! Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: What does the future hold for new EGFR targeting NSCLC therapies? [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...